Helsinn grants Stendhal rights to NEPA in several Latin America countries

Family-run Swiss oncology specialist Helsinn has granted exclusive rights to Mexico-based Especificos Stendhal for NEPA, an oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Under the deal, financial terms of which were not disclosed, marketing and distribution rights have been granted to Stendhal for Mexico, Venezuela, Colombia, Peru, Ecuador and most of Central American countries.

NEPA is already approved in the USA with the trade name Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Japanese drugmaker Eisai (TYO; 4523) has marketing rights for the drug in the USA. NEPA is currently in the registration phase in Europe and will be soon submitted to other regulatory authorities in the territories included in the agreement between Helsinn and Stendhal, for the prevention of CINV.